Anxiety and depressive disorders in cardiac patients
https://doi.org/10.51922/2616-633X.2024.8.1.2193
Abstract
Anxiety-depressive disorders (ADD) are often found in patients with cardiovascular diseases (CVD). ADR reduces the quality of life, aggravates the course, increases the risk of complications of CVD. Timely diagnosis and effective treatment of ADR is most effective in primary healthcare. The article describes the characteristics of psychosomatic comorbidity in patients with various cardiac diseases, presents the features of the diagnosis and treatment of ADR in patients with CVD.
About the Authors
N. Protko
Institute of Advanced Training and Retraining of Healthcare Personnel of the Belarusian State Medical University
Belarus
Belarus
Minsk
A. Goryunov
UZ “40th City Clinical Polyclinic”
Belarus
Belarus
Minsk
N. Dergach
UZ “34th Central District Polyclinic”
Belarus
Belarus
Minsk
G. D. Sitnik
Institute of Advanced Training and Retraining of Healthcare Personnel of the Belarusian State Medical University
Belarus
Belarus
Minsk
N. Shpigun
Institute of Advanced Training and Retraining of Healthcare Personnel of the Belarusian State Medical University
Belarus
Belarus
Minsk
S. Borichevsky
UZ “40th City Clinical Polyclinic”
Belarus
Belarus
Minsk
V. Kostyukov
UZ “34th Central District Polyclinic”
Belarus
Belarus
Minsk
I. Pateyuk
Institute of Advanced Training and Retraining of Healthcare Personnel of the Belarusian State Medical University
Belarus
Belarus
Minsk
References
1. Volel B.A., Ternovaya E.S., Ermusheva А.A., Syrkina E.A., Ardzinba I.B. Rasstrojstvo lichnosti i serdechno-sosudistye zabolevaniya (na modeli arterial’noj gipertonii i ishemicheskoj bolezni serdca) [Personality disorder and cardiovascular diseases (in the model of arterial hypertension and coronary heart disease)]. Psihicheskie rasstrojstva v obshchej medicine, 2014, no. 1, pp. 4-13. (in Russian).
2. Psihicheskoe zdorove i hronicheskie somaticheskie zabolevaniya [electronic resource] [Mental health and chronic physical illness] / World Federation of Mental Health, 2023. Available at https://mokc.by/sites/default/files/ WMHD%202010_0.pdf (accessed 20 September 2023). (in Russian).
3. Trevozhnost i zabolevaniya serdca [electronic resource] [Anxiety and Heart Disease. Psychiatry and Neuroscienc. Available at: https://psyandneuro.ru/novosti/anxiety-anger-personality-and-heart-disease (accessed 10 October 2023) (in Russian).
4. Depressiya i drugie obshchie psihicheskie rasstrojstva [electronic resource] [Depression and Other Common Mental Disorders]. Global Health Estimates. World Health Organization. Available at: https://iris.who.int/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf (accessed 10 October 2023) (in Russian).
5. Galeeva K. Pogranichnye psihicheskie rasstrojstva i kachestvo zhizni pacientov na razlichnyh stadiyah arterial’noj gipertenzii [Borderline mental disorders and quality of life of patients at various stages of arterial hypertension] : diss. kand. med. nauk: 14.01.06. Tomsk, 2013, 180 p. (in Russian).
6. Alinovskaya, S.V. Affektivnye rasstrojstva u pacientov s kardial’noj patologiej [Affective disorders in patients with cardiac pathology]. Molodoj uchenyj, 2013, no. 5, pp. 790-792. (in Russian).
7. Janszky I., Ahnve S., Lundberg I., Hemmingsson T. Early-onset depression, anxiety, and risk of subsequent coronary heart disease: 37-year follow-up of 49,321 young Swedish men. J Am Coll Cardiol, 2010, vol. 56(1), pp. 31-37. doi: 10.1016/j.jacc.2010.03.033.
8. Katon, U.Dzh. Epidemiologiya i terapiya depressij u pacientov s hronicheskoj somaticheskoj patologiej (obzor) [Epidemiology and therapy of depression in patients with chronic somatic pathology (review)]. Psihicheskie rasstrojstva v obshchej medicine, 2012, no. 2, pp. 50-56. (in Russian).
9. Shtarik, S.Y. Komorbidnost arterial’noj gipertenzii i trevozhno-depressivnyh rasstrojstv sredi vzroslogo naseleniya krupnogo promyshlennogo centra Vostochnoj Sibiri [Comorbidity of arterial hypertension and anxiety-depressive disorders among the adult population of a large industrial center of Eastern Siberia:] : diss. doct. med. nauk: 14.01.14. Krasnoyarsk, 2010, 288 p. (in Russian).
10. Smulevich A.B., Volel B.A., Ternovaya E.S., Nikitina Yu.M. Primenenie preparata pantogam aktiv (D-, L-gopantenovaya kislota) v terapii kognitivnyh i trevozhnyh rasstrojstv u pacientov s arterial’noj gipertenziej [Use of the drug (D-, L-hopantenic acid) in the treatment of cognitive and anxiety disorders in patients with arterial hypertension]. Obozrenie psihiatrii i medicinskoj psihologii, 2017, no. 3, pp. 96-108. (in Russian).
11. Repin A., Lebedeva E., Klinicheskoe techenie zabolevaniya u pacientov s IBS v sochetanii s trevozhno-depressivnymi rasstrojstvami na fone dlitel’noj terapii antidepressantami [Clinical course of the disease in patients with coronary artery disease in combination with anxiety and depressive disorders during long-term antidepressant therapy]. Sibirskij Medicinskij zhurnal, 2010, vol. 25(2), no. 2, pp. 20-25. (in Russian).
12. Frasure-Smith N., Lespérance F. Depression and cardiac risk: present status and future directions. Heart, 2010, vol. 96(3), pp. 173-176. doi: 10.1136/hrt.2009.186957.
13. Vogelzangs N., Seldenrijk A., Beekman A., Hein P., J van Hout, Peter de Jonge, Brenda W., Penninx J. Cardiovascular disease in persons with depressive and anxiety disorders. J Affect Disord, 2010, vol. 125(1-3), pp. 241-248. doi: 10.1016/j.jad.2010.02.112.
14. Repin A. Depressivnye rasstrojstva u pacientov s IBS: vozmozhnosti diagnostiki i lecheniya v kardiologicheskom stacionare [Depressive disorders in patients with coronary artery disease: diagnostic and treatment options in a cardiology hospital]. Medicinskij vestnik. Available at: https://medvestnik.by/technology/depressivnye-rasstrojstva-u-patsientov-s-ibs-vozmozhnosti-diagnostiki-i-lecheniya-v-kardiologicheskom-statsionare (accessed 15 October 2023) (in Russian).
15. Kayano H., Koba S., Matsui T., Fukuoka H., Toshida T., Sakai T., Akutsu Y., Tanno K., Geshi E., Kobayashi Y. Anxiety disorder is associated with nocturnal and early morning hypertension with or without morning surge: ambulatory blood pressure monitoring. Circ J, 2012, vol. 76(7), pp. 1670-1677. doi: 10.1253/circj.cj-11-1085.
16. Player M., Peterson L. Anxiety disorders, hypertension, and cardiovascular risk : a review. Int J Psychiatry Med., 2011;41(4):365-77. doi: 10.2190/PM.41.4.f.
17. Andryushchenko, A.V. Psihicheskie i psihosomaticheskie rasstrojstva v uchrezhdeniyah obshchesomaticheskoj seti (kliniko-epidemiologicheskie aspekty, psihosomaticheskie sootnosheniya, terapiya) [Mental and psychosomatic disorders in institutions of the general somatic network (clinical and epidemiological aspects, psychosomatic relationships, therapy)] : diss. doct. med. nauk: 14.01.06. М., 2011, 385 p. (in Russian).
18. Carvalho A., McIntyre R. Mental Disorders in Primary Care A: Guide to their Evaluation and Management. Dialogues Clin Neurosci, 2003, vol. 5(2), pp. 115-128. doi: 10.31887/DCNS.2003.5.2/huwittchen.
19. Filippova N.V., Barylnik Yu.B., Bogdanova T.M., Blinova V.V., Shchelchkova A.A., Mozgacheva E.S. Effektivnost i bezopasnost Vortioksetina v terapii depressivnyh rasstrojstv u pacientov kardiologicheskogo profilya [Effectiveness and safety of vortioxetine in the treatment of depressive disorders in cardiac patients]. Obozrenie psihiatrii i medicinskoj psihologii im. V.M. Bekhtereva, 2023, vol. 57(2), pp. 105-115. doi: 10.31363/2313-7053-2023-817 (in Russian).
20. Wang Y., Nomikos G., Karim A., Munsaka M., Serenko M., Maggie Liosatos M. Effect of Vor tioxetine on Cardiac Repolarization in Healthy Adult Male Subjects: Results of a Thorough QT/QTc Study. Clin Pharmacol Drug Dev, 2013, vol. 2(4), pp. 298-309. doi: 10.1002/cpdd.51.
21. Grace C., Zhang W., Serenko M. Lack of Effect of Multiple Doses of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Aspirin and Warfarin. J Clin Pharmacol, 2015, vol. 55(6), pp. 671-679. doi: 10.1002/jcph.456.
22. Baldwin D.S., Necking O., Schmidt S.N., Ren H., Reines E. H. Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness. J Affect Disord, 2022, vol. 15(3110, pp. 588-594. doi: 10.1016/j.jad.2022.05.098.
23. Alfonso C.T., Pérez-Mandujano A., Ramírez-González R.I., Freasan A. Vortioxetine versus sertraline in metabolic control, distress and depression in Mexican patients with type 2 diabetes. Ann Transl Med, 2019, vol. 7(22), pp. 656-656. doi: 10.21037/atm.2019.10.56.
24. Quilichini J.B., Revet A., Garcia P., Bouquié R., Hamard J., Yrondi A., Montastruc F. Comparative effects of 15 antidepressants on the risk of withdrawal syndrome: A real-world study using the WHO pharmacovigilance database. J Affect Disord, 2022, vol. 15(297), pp. 189-193. doi: 10.1016/j.jad.2021.10.041.
25. Shakurai H., Uchida H., Kato M., Suzuki T., Baba H., Watanabe K., Inada K., Kikuchi T., Katsuki A., Kishida I., Sugawara Kikuchi Y., Yasui-Furukori N. Pharmacological management of depression: Japanese Expert Consensus. J Affect Disord. 2020, vol. 266, pp. 626-632. doi: 10.1016/j.jad.2020.01.149.
26. Kollhorst B., Jobski K., Krappweis J., Schink T., Garbe E., Schmedt N. Antidepressants and the risk of death in older patients with depression. A population-based cohort study. PLoS One, 2019, vol. 14(4), pp. e0215289. doi: 10.1371/journal.pone.0215289.
Review
For citations:
Protko N., Goryunov A., Dergach N., Sitnik G.D., Shpigun N., Borichevsky S., Kostyukov V., Pateyuk I. Anxiety and depressive disorders in cardiac patients. Emergency Cardiology and Cardiovascular Risks journal. 2024;8(1):2193-2200. (In Russ.) https://doi.org/10.51922/2616-633X.2024.8.1.2193
Views:
27
Email this article 